Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From <scp>JAK,</scp> an International Registry Collaboration

OBJECTIVE: To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin-6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK-pot collaboration. METHODS: We analyzed 21,675 treatment courses for model training, 5,418 courses for internal validation, and 1,807 courses from Switzerland for external validation. Remission was defined as a Clinical Disease Activity Index score ≤2.8 within 6 to 24 months after treatment initiation or switching. An XGBoost model was trained on 63 baseline demographic and clinical variables. Model performance was evaluated using the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Predictor contributions were quantified using Shapley Additive Explanations values. A simplified model using the top 10 predictors and a logistic regression benchmark were also evaluated. RESULTS: In external validation, the full model achieved an AUC of 0.797 (95% confidence interval 0.774-0.821), sensitivity of 0.804, specificity of 0.650, PPV of 0.454, and NPV of 0.902. The simplified model performed comparably (AUC 0.802). Logistic regression using the same 10 predictors achieved an AUC of 0.809. Key predictors included patient global assessment, 28-tender joint count, previous biologic/targeted synthetic disease-modifying antirheumatic drug exposure, and Health Assessment Questionnaire Disability Index score. CONCLUSION: Using routinely collected baseline data across 11 registries, prediction of remission showed limited discrimination and was best suited to ruling out remission. Performance was similar for a 10-variable model and logistic regression, indicating limited incremental value of model complexity without richer predictors.

Authors

Institutions

Publication Details

Journal
Arthritis & Rheumatology
Published
2026-04-06
DOI
https://doi.org/10.1002/art.70165
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Axel Finckh, A. R. A. RODRIGUES, Jakub Závada, Céline Lamacchia et al.
Arthritis & Rheumatology
Rheumatoid Arthritis Research and Therapies
article

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Axel Finckh, A. R. A. RODRIGUES, Jakub Závada, Céline Lamacchia, K. Lauper, Nina Trokovic, Dan Nordström, C. Codreanu, T.K. Kvien, D. Choquette, Irini D. Flouri, Zübeyir Salis, Ruth Fritsch‐Stork, Louis Coupal, Denis Mongin, Roberto Caporali, Delphine Courvoisier, Karel Pavelka, Florenzo Iannone, Michele Iudici, Prodromos Sidiropoulos, Ziga Rotar, Sella Provan
article en

Abstract

OBJECTIVE: To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin-6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK-pot collaboration. METHODS: We analyzed 21,675 treatment courses for model training, 5,418 courses for internal validation, and 1,807 courses from Switzerland for external validation. Remission was defined as a Clinical Disease Activity Index score ≤2.8 within 6 to 24 months after treatment initiation or switching. An XGBoost model was trained on 63 baseline demographic and clinical variables. Model performance was evaluated using the area under the curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Predictor contributions were quantified using Shapley Additive Explanations values. A simplified model using the top 10 predictors and a logistic regression benchmark were also evaluated. RESULTS: In external validation, the full model achieved an AUC of 0.797 (95% confidence interval 0.774-0.821), sensitivity of 0.804, specificity of 0.650, PPV of 0.454, and NPV of 0.902. The simplified model performed comparably (AUC 0.802). Logistic regression using the same 10 predictors achieved an AUC of 0.809. Key predictors included patient global assessment, 28-tender joint count, previous biologic/targeted synthetic disease-modifying antirheumatic drug exposure, and Health Assessment Questionnaire Disability Index score. CONCLUSION: Using routinely collected baseline data across 11 registries, prediction of remission showed limited discrimination and was best suited to ruling out remission. Performance was similar for a 10-variable model and logistic regression, indicating limited incremental value of model complexity without richer predictors.

Arthritis & Rheumatology
Sigmund Freud Privatuniversität Wien (AT), University of Geneva (CH), University of Crete (GR), University of Ljubljana (SI), University of Milan (IT), Österreichischer Rundfunk (AT), Ljubljana University Medical Centre (SI), Physiologie et Médecine Expérimentale du Coeur et des Muscles (FR), Institute of Rheumatology (CZ), Bioforschung Austria (AT), Sociedade Portuguesa de Cardiologia (PT), University Hospital of Geneva (CH), Institute for Rheumatic Diseases (Japan) (JP), Diakonhjemmet Hospital (NO), Centre Hospitalier de l’Université de Montréal (CA), Crete University Press (GR), Hospital District of Helsinki and Uusimaa (FI), University of Bari Aldo Moro (IT), Universidade Nova de Lisboa (PT), Foundation for Research and Technology Hellas (GR)
Reduced inequalities
Openalex Percentile: Top 35%
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.